Approval · Notice of Compliance 36248 · 2025
TRIUMEQ: Notice of Compliance 36248
Issued October 24, 2025
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 36248
- Date
- October 24, 2025
- Company
- Viiv Healthcare UlcMontreal, Quebec, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Other
- Reason
- Update to the Product Monograph with new safety information
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| TRIUMEQ | Not yet assigned | — |
Medicinal ingredients
- LAMIVUDINE 300 MG per TAB
- ABACAVIR SULFATE 600 MG per TAB
- DOLUTEGRAVIR SODIUM 50 MG per TAB